Affimed’s Promising Clinical Update on NSCLC Treatment

Affimed ( (AFMD) ) has shared an announcement.

Affimed has reported promising results from its AFM24/atezolizumab combination therapy in heavily pretreated non-small cell lung cancer (NSCLC) patients. The treatment demonstrated significant clinical activity, with a 21% overall response rate in EGFR wild-type patients and a 24% rate in EGFR mutant patients. The company intends to advance the therapy by increasing the dosage to 720 mg weekly, following evidence that higher exposure improves response rates and survival outcomes.

More about Affimed

Affimed N.V. is a clinical-stage immuno-oncology company based in Mannheim, Germany. It focuses on leveraging the innate immune system to combat cancer, utilizing its proprietary ROCK® platform to create innate cell engagers (ICE®) that target and destroy tumor cells. The company’s product pipeline includes several ICE® molecules for treating hematologic and solid tumors.

YTD Price Performance: -65.92%

Average Trading Volume: 201,129

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $32.43M

For a thorough assessment of AFMD stock, go to TipRanks’ Stock Analysis page.